$JUNS News

Jupiter Neurosciences Initiates Patient Enrollment In Its Phase 2a RESET Clinical Study For JOTROL In Parkinson's Disease

Jupiter Neurosciences Files Prospectus For Offering 7.143M Common Shares

Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal

Jupiter Neurosciences To Acquire U.S. Licensing Rights To ALA-002 From Pharmala Biotech For $3.33M, Comprising $1.5M In Cash And $1.83M Of JUNS Stock

Jupiter Neurosciences Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $18.652K Miss $225.000K Estimate

Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14

Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board

Jupiter Neurosciences to Present at Emerging Growth Conference on April 2

Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026

Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago

Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution

Jupiter Neurosciences Enters Into Omnibus Amendment With YA II PN, Modifying Installment Payment Provisions Of Convertible Promissory Notes Issued Under Standby Equity Purchase Agreement

Jupiter Neurosciences Selected as B2i Digital Featured Company

Jupiter Neurosciences shares are trading lower. The company announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia consumer longevity product line.

Jupiter Neurosciences shares are trading lower. The company announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia consumer longevity product line.

Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

Jupiter Neurosciences Broadens Nugevia Market Opportunity By Targeting Growing Global Adoption Of GLP-1-Based Weight Loss Therapies

Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6

$50B+ Longevity Opportunity: Jupiter Neurosciences CEO Christer Rosen & President Alison Silva, Live at Nasdaq